DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

TRANSMITTAL OF ADVERTISEMENTS AND PROMOTIONAL LABELING FOR DRUGS AND BIOLOGICS FOR HUMAN USE

Form Approved: OMB No. 0910-0001 Expiration Date: March 31, 2024 See PRA Statement on last page.

1. Date Submitted 09/24/2021

Multiple products For multiple products, submit completed form and 2. Application Information X Single product specimen of advertising/promotional materials to one Application Type: BLA application of choice, and attach separate sheet addressing items 3-5 for remainder of products, Refer Application Number: 125742 / to No. 3 on instruction sheet. NOTE: Form FDA 2253 is required by law. Reports are required for approved NDAs, ANDAs (21 CFR 314.81), and BLAs (601.12(f)(4)) 3. Proprietary Name 4. Established Name [COVID-19 mRNA Vaccine (nucleoside modified)] **COMIRNATY** Product Code No.: 5. Package Insert Date and ID Number 6. Manufacturer Name (Latest final printed labeling) 08/21 LAB-1448-1.0 License No. (Biologics): Advertisement / Promotional Labeling Materials × Professional a. Please check only one: Consumer Material Type Dissemination/ Material ID Code Material Description (use FDA codes) Publication Date C. Promotional Labeling 09/24/2021 PP-CVV-USA-0389 COMIRNATY LDV Resource Sheet 16+ US EUA BLA Delete Row Promotional Labeling 09/24/2021 PP-CVV-USA-0387 COMIRNATY 16+ BLA Checklist US August 2021 Delete Row To delete a row, click the "Delete Row" button for that row (or press the enter key Add New Row if you've tabbed into the button). You cannot delete the last remaining row. f. Comments PP-CVV-USA-0387 is an updated version of PP-CVV-USA-0310 which is non-reportable.

8.	Applicant's (or Agent's) Return Address	9. Responsible Official's (or Agent's)				
	Address 1 (Street address, P.O. box, company name c/o)			a. Telephone Number (Include area code)		
	An der Goldgrube 12 Address 2 (Apartment, suite, unit, building, floor, etc.)			(484) 865-5035		
				b. FAX Number (Include area code)		
				(845) 474-3500		
	City	State/Province/Region N/A ZIP or Postal Code				
	Mainz			c. Email Address Donna.Boyce@pfizer.com		
	Country					
	Germany		55131			
10	. Typed Name and Title of Responsible Offici	ial or Ager	nt 11. Signature of Responsible Officia	al or Agent	12. Date	
Donna Boyce M.S., Senior Vice President, Global Regulatory Affairs, Global Product Development			(b) (6) Digitally signed by (6) (6) DN or Piffer the in (b) (6) Reason I am signing on binal of Donna Boyce Location (b) (6) Date 20(1.0) 2 09 2 11 08 00		09/24/2021	
13	13. For CBER Products Only (Check one)					
Draft ★ Final						

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 2 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."